Global Blood Therapeutics (NASDAQ:GBT) Downgraded by William Blair
Global Blood Therapeutics (NASDAQ:GBT) Downgraded by William Blair
William Blair cut shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) from an outperform rating to a market perform rating in a report issued on Monday, MarketBeat reports. William Blair also issued estimates for Global Blood Therapeutics' Q3 2022 earnings at ($1.26) EPS, Q4 2022 earnings at ($1.21) EPS, FY2022 earnings at ($4.98) EPS, Q1 2023 earnings at ($1.14) EPS, Q2 2023 earnings at ($1.09) EPS, Q3 2023 earnings at ($1.03) EPS, Q4 2023 earnings at ($0.96) EPS and FY2023 earnings at ($4.22) EPS.
据MarketBeat报道，威廉·布莱尔在周一发布的一份报告中将全球血液治疗公司(纳斯达克：GBT-GET评级)的股票从表现优于市场的评级下调至市场表现评级。威廉·布莱尔还发布了对全球血液治疗公司2022年第三季度每股收益(1.26美元)、2022年第四季度每股收益(1.21美元)、2022年第一季度每股收益(4.98美元)、2023年第一季度每股收益(1.14美元)、2023年第二季度每股收益(1.09美元)、2023年第三季度每股收益(1.03美元)、2023年第四季度每股收益(0.96美元)和2023财年每股收益(4.22美元)的预期。
GBT has been the subject of a number of other reports. Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a hold rating to a buy rating and lifted their target price for the company from $40.00 to $72.00 in a research note on Monday. Oppenheimer reduced their target price on shares of Global Blood Therapeutics from $86.00 to $71.00 in a research note on Thursday, May 5th. JPMorgan Chase & Co. reduced their price objective on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a neutral rating for the company in a research note on Tuesday, June 28th. Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a hold rating to a buy rating and boosted their price objective for the stock from $40.00 to $72.00 in a research note on Monday. Finally, StockNews.com upgraded shares of Global Blood Therapeutics from a sell rating to a hold rating in a research note on Thursday, May 5th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Global Blood Therapeutics currently has a consensus rating of Hold and an average target price of $65.04.
GBT一直是其他一些报告的主题。周一，Canaccel Genuity Group在一份研究报告中将全球血液治疗公司的股票评级从持有评级上调为买入评级，并将该公司的目标价从40.00美元上调至72.00美元。奥本海默在5月5日星期四的一份研究报告中将全球血液治疗公司的股票目标价从86.00美元下调至71.00美元。摩根大通在6月28日星期二的一份研究报告中将全球血液治疗公司的股票目标价从39.00美元下调至36.00美元，并为该公司设定了中性评级。周一，Canaccel Genuity Group在一份研究报告中将全球血液治疗公司的股票评级从持有评级上调为买入评级，并将其股票目标价从40.00美元上调至72.00美元。最后，StockNews.com在5月5日星期四的一份研究报告中将全球血液治疗公司的股票评级从卖出评级上调为持有评级。10名研究分析师对该股的评级为持有，6名分析师对该公司股票的评级为买入。根据MarketBeat的数据，全球血液治疗公司目前的共识评级为持有，平均目标价为65.04美元。
Global Blood Therapeutics Stock Performance
全球血液治疗公司股票表现
GBT stock opened at $66.57 on Monday. The company has a debt-to-equity ratio of 4.92, a quick ratio of 7.74 and a current ratio of 6.88. The stock has a market cap of $4.33 billion, a P/E ratio of -13.29 and a beta of 0.83. The firm has a 50 day simple moving average of $34.55 and a 200 day simple moving average of $31.84. Global Blood Therapeutics has a 52 week low of $21.65 and a 52 week high of $73.02.
GBT股票周一开盘报66.57美元。该公司的负债权益比率为4.92，速动比率为7.74，流动比率为6.88。该股市值为43.3亿美元，市盈率为-13.29，贝塔系数为0.83。该公司的50日简单移动均线切入位为34.55美元，200日简单移动均线切入位为31.84美元。全球血液治疗公司的52周低点为21.65美元，52周高点为73.02美元。
Insider Buying and Selling
内幕买卖
In related news, Director Philip A. Pizzo sold 1,260 shares of the business's stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $27.25, for a total transaction of $34,335.00. Following the transaction, the director now owns 9,112 shares of the company's stock, valued at $248,302. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.90% of the stock is currently owned by insiders.
在相关新闻中，董事菲利普·A·皮佐在6月21日(星期二)的一次交易中出售了1260股该公司的股票。这些股票以27.25美元的平均价格出售，总成交额为34,335.00美元。交易完成后，董事现在持有该公司9,112股股票，价值248,302美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份法律文件中披露的，该文件可通过以下超级链接获得。4.90%的股份目前由内部人士持有。
Institutional Investors Weigh In On Global Blood Therapeutics
机构投资者参与全球血液治疗
Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its holdings in Global Blood Therapeutics by 75.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after buying an additional 650 shares during the period. ProShare Advisors LLC boosted its stake in shares of Global Blood Therapeutics by 7.6% in the 4th quarter. ProShare Advisors LLC now owns 22,609 shares of the company's stock valued at $662,000 after purchasing an additional 1,603 shares in the last quarter. Toronto Dominion Bank acquired a new stake in shares of Global Blood Therapeutics in the 4th quarter valued at $3,015,000. Vestmark Advisory Solutions Inc. boosted its stake in shares of Global Blood Therapeutics by 44.3% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company's stock valued at $439,000 after purchasing an additional 3,892 shares in the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Global Blood Therapeutics in the 4th quarter valued at $577,000.
机构投资者和对冲基金最近买卖了该公司的股票。NISA Investment Advisors LLC在第一季度增持了75.6%的全球血液治疗公司的股份。NISA Investment Advisors LLC现在持有1,510股该公司股票，价值52,000美元，在此期间又购买了650股。ProShare Advisors LLC在第四季度将其在全球血液治疗公司的股份增加了7.6%。ProShare Advisors LLC现在拥有22,609股该公司股票，价值662,000美元，上个季度又购买了1,603股。多伦多道明银行在第四季度收购了全球血液治疗公司的新股份，价值301.5万美元。Vestmark Consulting Solutions Inc.在第一季度增持了全球血液治疗公司的股份44.3%。Vestmark Consulting Solutions Inc.现在持有12,669股该公司股票，价值43.9万美元，该公司在上个季度又购买了3,892股。最后，First Trust Advisors LP在第四季度收购了全球血液治疗公司的新股份，价值57.7万美元。
About Global Blood Therapeutics
关于全球血液治疗公司
(Get Rating)
(获取评级)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治疗公司是一家生物制药公司，致力于发现、开发和提供针对服务不足的镰状细胞疾病(SCD)患者群体的治疗方法。该公司提供Oxbryta片剂，这是一种治疗SCD的口服药物，每天一次。它还在第二阶段对青少年和儿童SCD患者的临床试验中评估了单剂和多剂Oxbryta的安全性和药代动力学。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免费获取StockNews.com关于全球血液治疗(GBT)的研究报告
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票？
- 找到并获利于52周低点的股票交易
- 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
- 清洁能源法案通过后，太阳能股大放异彩
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对全球血液治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。